Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment—a once-monthly injection into the eye.

Kodiak believes it can do better with an experimental drug that may require less frequent injections and the company has filed for an to finance a slate of global clinical . Palo Alto, CA-based Kodiak set a preliminary $100 million target for its stock offering. The company has applied for a listing on the Nasdaq exchange under the stock symbol “KOD.” (Kodiak is not to be confused with Cambridge, MA-based Codiak BioSciences.)… Read more »


Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.